Stocks Health care RIGL
NASDAQ · Health careRigel Pharmaceuticals Inc (RIGL)
Rigel Pharmaceuticals Inc brought in $288.2M of revenue over the twelve months to September 30, 2026, up 2.2% from a year earlier. Net income was $307.2M, a net margin of 106.6%. At September 30, 2026 it held $46.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Rigel Pharmaceuticals Inc
- Net worth
- Rigel Pharmaceuticals Inc has a market value (market cap) of $785.5M at the latest share price, and shareholders' equity of $445.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations brought in $75.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Rigel Pharmaceuticals Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Rigel Pharmaceuticals Inc does
Rigel Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RIGL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $294.3M | $367M | $19.48 | n/a |
| 2024 | $179.3M | $17.5M | $0.99 | n/a |
| 2023 | $116.9M | -$25.1M | -$1.44 | n/a |
| 2022 | $120.2M | -$58.6M | -$3.44 | -$74.2M |
| 2021 | $149.2M | -$17.9M | -$1.11 | $5.3M |
| 2020 | $108.6M | -$29.7M | -$1.82 | -$53.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RIGL ranks in Health care
Latest SEC filings
What Rigel Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 16% to $80.9M versus the same quarter last year; diluted EPS $0.65 versus $1.46.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026
- August 4, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 23% to $78.7M versus the same quarter last year; diluted EPS $0.88 versus $3.28.
- July 1, 2026
- June 17, 2026
- May 20, 2026
Insider trades
What the people running Rigel Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 8 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 2, 2026 | Schorno Dean LEVP & Chief Financial Officer | Exercised options | 694 | $8.8K |
| September 2, 2026 | Schorno Dean LEVP & Chief Financial Officer | Exercised options | 620 | $11.6K |
| September 2, 2026 | Schorno Dean LEVP & Chief Financial Officer | Exercised options | 2,000 | $48.4K |
| September 2, 2026 | Schorno Dean LEVP & Chief Financial Officer | Exercised options | 1,286 | $31.1K |
| September 1, 2026 | Furey Raymond J.EVP, GC, CCO & Corp Sec | Shares withheld for tax | 877 | $41.7K |
| September 1, 2026 | Rodriguez Raul RCEO, President, Director | Shares withheld for tax | 2,424 | $115.1K |
| September 1, 2026 | Santos David AEVP, Chief Commercial Officer | Shares withheld for tax | 874 | $41.5K |
| September 1, 2026 | Schorno Dean LEVP & Chief Financial Officer | Shares withheld for tax | 928 | $44.1K |
Who owns RIGL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Soleus Capital Master Fund, L.P.13G, passive with 5 related filers | 9.9% | August 13, 2026 |
| Armistice Capital, LLC13G, passive with 1 related filers | 8.95% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 155 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 1,939,818 | +170,911 |
| Soleus Capital Management, L.P. | 1,843,504 | +1,833,504 |
| Armistice Capital, LLC | 1,672,000 | +392,000 |
| State Street Corp | 1,039,994 | -80,244 |
| Vanguard Capital Management LLC | 785,107 | +20,914 |
| American Century Companies Inc | 741,718 | +197,287 |
| D. E. Shaw & Co., Inc. | 542,539 | +96,861 |
| Geode Capital Management, LLC | 483,175 | +42,549 |
| Marshall Wace, Llp | 367,393 | -230,985 |
| CM Management, LLC | 250,000 | +15,000 |
| Vanguard Portfolio Management LLC | 233,728 | +86,193 |
| Dimensional Fund Advisors LP | 227,951 | -151,590 |
| Goldman Sachs Group Inc | 226,780 | -212,321 |
| Two Sigma Investments, LP | 207,578 | -198,229 |
| Nomura Asset Management International Inc. | 195,000 | new |
| Morgan Stanley | 186,049 | +87,181 |
| Charles Schwab Investment Management Inc | 154,627 | -22,223 |
| Northern Trust Corp | 146,381 | +11,811 |
| Renaissance Technologies LLC | 145,846 | -192,595 |
| O'Shaughnessy Asset Management, LLC | 131,177 | +5,515 |
Insiders
12 insiders reported holding 615,567 shares in total, about $25.9M at the last price.
| Holder | Shares |
|---|---|
| Rodriguez Raul RCEO, President, Director | 273,362 |
| Schorno Dean LEVP & Chief Financial Officer | 82,962 |
| Santos David AEVP, Chief Commercial Officer | 61,622 |
| Furey Raymond J.EVP, GC, CCO & Corp Sec | 50,559 |
| Hannah Alison L.EVP, Chief Medical Officer | 35,025 |
| Rojkjaer LisaEVP, Chief Medical Officer | 34,003 |
| Moos Walter HDirector | 18,472 |
| Wasman JaneDirector | 18,250 |
| Lapointe Anthony GreggDirector | 18,250 |
| Ali-Jackson KamilDirector | 10,125 |
Questions about RIGL
What does Rigel Pharmaceuticals Inc do?
Rigel Pharmaceuticals Inc is a company in the Health care sector, listed on NASDAQ as RIGL. Its shares trade on NASDAQ under the ticker RIGL.
What is Rigel Pharmaceuticals Inc's net worth?
Rigel Pharmaceuticals Inc has a market value (market cap) of $785.5M at the latest share price, and shareholders' equity of $445.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Rigel Pharmaceuticals Inc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $307.2M on revenue of $288.2M, a net margin of 106.6%.
How much revenue does Rigel Pharmaceuticals Inc make?
Over the twelve months to September 30, 2026 Rigel Pharmaceuticals Inc reported revenue of $288.2M. That is 2.2% more than a year earlier.
When did Rigel Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Rigel Pharmaceuticals Inc's next earnings report?
Rigel Pharmaceuticals Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RIGL with
Follow RIGL
Get an email when Rigel Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Rigel Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.